Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + trastuzumab + taxane in first-line HER2-positive advanced breast cancer
NL-OMON47342Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pertuzumab in breast cancer, sponsored by Roche. Primary endpoint: Safety and tolerability. Started Jun 2012; status: active, not recruiting.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON47342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47342.